Alfonso Wassermann founded the pharmaceutical laboratory A.Wassermann and Cia. A.S. in Milan
The "Society Italo-Spanish from pharmacotherapeutic specialties" was founded in Barcelona, in order to manufacture and market pharmaceutical products.
The company acquires a greater boom in continuous capital increases; Spanish partners become part of the shareholders.
Wassermann is the first laboratory that synthesizes, records and commercializes sulfa drug in Spain
New installations are built for manufacturing pharmaceutical products and active principles
Wassermann Italy and Wassermann Spain stop having common shareholders.
Potentiation of research with the cytostatic fabrication plant.
Consolidation of a center for chemical-pharmacological research.
The patent of manufacturing process for etofenamate is developed.
Biniwas (Binifibrate) is launched on the market, for lipid lowering micro- hemorrheologic, this product is designed, synthesized and pharmacologically and clinically developed in the R & D laboratory. It was licensed in various countries.
Publication of the "negative list", affects about 50% of total invoicing of the company.
Chiesi Farmaceutici S.p.A., purchases Laboratory Wassermann. The Spanish subsidiary changes its name to, Chiesi Spain, S.A.. Closing of the industrial center in Spain and focusing only on business.